Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Employees test procedures for manufacturing mRNA for the COVID-19 vaccine in a BioNTech facility. Photo: Abdulhamid Hosbas/Anadolu Agency via Getty Images

BioNTech announced this week that it plans to establish mRNA vaccine production facilities in Africa, according to the Financial Times.

Why it matters: The blockbuster success of mRNA vaccines for the COVID-19 pandemic could give a boost to efforts to use the adaptable technology to tackle cancers, malaria and other intractable illnesses, as Axios has previously reported.

  • Africa has long been neglected by pharmaceutical companies, and establishing mRNA production capabilities could greatly improve the continent's prospects of combatting diseases — COVID-19 and beyond.

Context: The announcement — made jointly between BioNTech co-founder and chief executive Uğur Şahin and European Commission President Ursula von der Leyen — comes as countries in Africa have struggled to keep pace with wealthier nations in vaccinating their citizens against COVID-19.

  • The total number of COVID-19 vaccinations completed in Africa — about 39 million — accounts for just over 2% of global vaccinations, according to FT.
  • Additionally, Africa imports more than 99% of the vaccines it uses.

Details: Though still in its early stages, experts are optimistic that vaccines and therapies based on mRNA hold promise to combat infections from viruses like HIV and influenza that other vaccines have struggled to quash, according to Axios' Alison Snyder.

  • BioNTech's push to establish capacity in Africa for the early, highly technical stages of mRNA manufacturing could take about four years to complete, according to Şahin.
  • In the short term, BioNTech is planning to train a partner in Africa to "fill and finish" vaccine doses in approximately 12 months, allowing the continent to import large quantities of vaccines more efficiently, Şahin says.

What they're saying: "From the technology side, there is no reason why [vaccine production in Africa] should not be possible," Şahin told FT. “We are joining forces in a way that everyone brings in the best competences they have.”

What's next: Şahin is likely to urge nations to expand their COVID-19 vaccine exports globally at the G7 summit in England this week, per FT.

Go deeper

The global vaccine supply is finally opening up

Illustration: Brendan Lynch/Axios

The global vaccine supply is finally opening up for countries that desperately need the ammo in the fight against the COVID-19 pandemic.

Driving the news: The Biden administration will buy 500 million doses of the Pfizer-BioNTech coronavirus vaccine to share with countries around the world, with the option to buy an additional 200 million.

U.S. to buy 500 million Pfizer doses to share with the world

Photo: Anna Moneymaker/Getty Images

The Biden administration will buy 500 million doses of the Pfizer-BioNTech coronavirus vaccine to share with countries around the world, with the option to buy an additional 200 million, two sources familiar with the deal tell Axios.

Why it matters: That's a big step toward making the U.S. a major global vaccine supplier and comes as Biden departs for his first foreign trip as president.

Updated 14 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Brendan Lynch/Axios

  1. Health: Emergency room visits of all kinds dropped amid the pandemic — NY smart-thermometer network could predict next COVID wave.
  2. Vaccines: FDA clears 10 million J&J vaccine doses from contaminated Baltimore plant — Moderna asks FDA to expand COVID-19 vaccine authorization to adolescents.
  3. Cities: Seattle becomes first major city to get 70% fully vaccinated — Schools nationwide prepare for packed kindergartens this fall.
  4. Work: Goldman Sachs requires U.S. employees to report vaccination status.
  5. Politics: U.S. to buy 500 million Pfizer doses to share with the world — State Department eases travel advisories for dozens of countries.
  6. World: Moscow orders new restrictions amid surge in COVID-19 cases — 12 Venezuela players, staff contract COVID-19 before Copa America opener — 2021 already has a higher global coronavirus death toll than 2020.
  7. 🎧 Podcast: Back to normal without herd immunity.
  8. Variant tracker: Where different strains are spreading.